2132. Surveillance of Eravacycline Against Enterobacterales and Non-Fermenter Clinical Isolates, Including Resistant Isolates, Collected Worldwide from Multiple Infection Sites During 2021

BACKGROUND: Eravacycline is a fully synthetic, fluorocycline approved for the treatment of complicated intra-abdominal infections (cIAI) in patients ≥18 years of age in Europe, Singapore, Hong Kong, mainland China, the US, and the UK. The purpose of this study was to monitor the in vitro activity of eravacycline against 2,942 Gram-negative clinical isolates, including multidrug-resistant (MDR) isolates, collected worldwide in 2021. METHODS: As part of a worldwide surveillance study, a total of 2,942 Gram-negative isolates were collected during 2021 from various infections including IAI, body fluids, respiratory and other sources. Of the 2,942 isolates, 654, 1263, and 1025 were from Asia/Pacific, Europe, and North America, respectively. Minimum inhibitory concentrations (MICs) were determined by CLSI broth microdilution. Antibiotic susceptibility was determined with FDA or CLSI breakpoints. RESULTS: Summary MIC data for tested antimicrobials are shown in the Table. Susceptibility to eravacycline for Enterobacterales was 93.9%, 85.7%, 90.0%, and 96.8% for all isolates, MDR Enterobacterales, ESBL-positive, and ESBL-negative isolates, respectively. Although there are no clinical breakpoints for Acinetobacter baumannii or Stenotrophomonas maltophilia, eravacycline exhibited promising activity against these species with MIC(50) / MIC(90) of 0.5 & 1 and 1 & 2 µg/ml, respectively. [Figure: see text] [Figure: see text] CONCLUSION: Eravacycline exhibited sustained high susceptibility against multiple Enterobacterales species, including MDR and ESBL-positive isolates. While breakpoints are not defined for A. baumannii or S. maltophilia, eravacycline demonstrated promising activity against these species. These results suggest that, following several years of clinical use, susceptibility to eravacycline remains high. DISCLOSURES: Stephen Hawser, PhD, Allecra: study funding|Innoviva Specialty Therapeutics, Inc.: Honoraria|Roche: Honoraria|Roche: This project has been funded by BARDA (HHSO100201600038C). Nimmi Kothari, PhD, Allecra: Allecra (study funding)|Innoviva Specialty Therapeutics, Inc.: Honoraria|Roche: Honoraria|Roche: This project has been funded by BARDA (HHSO100201600038C). Federica Monti, PhD, Allecra: Study funded|Innoviva Specialty Therapeutics, Inc.: Honoraria Tony Hodges, MD, La Jolla Pharmaceutical Company: Employee|La Jolla Pharmaceutical Company: Stocks/Bonds Kristie Zappas, PhD, La Jolla Pharmaceutical Company: employee|La Jolla Pharmaceutical Company: Stocks/Bonds